Interpace Biosciences (OTCPK:IDXG) - Share price, News & Analysis

IDXG fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

IDXG Stock Overview

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.

Rewards

Revenue is forecast to grow 15.16% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($10M)

Interpace Biosciences Competitors

G Medical Innovations Holdings

NasdaqCM:GMVD

US$9.1m

Star Equity Holdings

NasdaqGM:STRR

US$15.7m

Cannabis Sativa

OTCPK:CBDS

US$4.8m

American Shared Hospital Services

NYSEAM:AMS

US$14.7m

Price History & Performance

Summary of all time highs, changes and price drops for Interpace Biosciences
Historical stock prices
Current Share Price	US$2.41
52 Week High	US$10.33
52 Week Low	US$1.67
Beta	1.01
1 Month Change	-5.49%
3 Month Change	-29.12%
1 Year Change	-73.66%
3 Year Change	-68.31%
5 Year Change	-82.91%
Change since IPO	-99.89%

Shareholder Returns

	IDXG	US Healthcare	US Market
7D	-0.4%	1.8%	0.3%
1Y	-73.7%	14.3%	-13.5%

Return vs Industry: IDXG underperformed the US Healthcare industry which returned 14.3% over the past year.

Return vs Market: IDXG underperformed the US Market which returned -13.5% over the past year.

Price Volatility

Is IDXG's price volatile compared to industry and market?
IDXG volatility
IDXG Average Weekly Movement	12.2%
Healthcare Industry Average Movement	9.0%
Market Average Movement	7.9%
10% most volatile stocks in US Market	17.2%
10% least volatile stocks in US Market	3.2%

Stable Share Price: IDXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: IDXG's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1986	147	Tom Burnell	https://www.interpace.com

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.

Interpace Biosciences Fundamentals Summary

How do Interpace Biosciences's earnings and revenue compare to its market cap?
IDXG fundamental statistics
Market Cap	US$10.19m
Earnings (TTM)	-US$12.79m
Revenue (TTM)	US$41.86m

0.2x

P/S Ratio

-0.8x

P/E Ratio

Is IDXG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDXG income statement (TTM)
Revenue	US$41.86m
Cost of Revenue	US$23.44m
Gross Profit	US$18.42m
Other Expenses	US$31.21m
Earnings	-US$12.79m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-3.02
Gross Margin	44.01%
Net Profit Margin	-30.55%
Debt/Equity Ratio	470.8%

How did IDXG perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is IDXG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDXG?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for IDXG. This is calculated by dividing IDXG's market cap by their current preferred multiple.
What is IDXG's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$10.19m

IDXG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	-10x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does IDXG's PS Ratio compare to its peers?

IDXG PS Ratio vs Peers

The above table shows the PS ratio for IDXG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	1.4x
GMVD G Medical Innovations Holdings	1.8x	n/a	US$9.1m
STRR Star Equity Holdings	0.1x	7.7%	US$15.7m
CBDS Cannabis Sativa	2.7x	n/a	US$4.8m
AMS American Shared Hospital Services	0.8x	n/a	US$14.7m
IDXG Interpace Biosciences	0.2x	15.2%	US$10.2m

Price-To-Sales vs Peers: IDXG is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.4x).

Price to Earnings Ratio vs Industry

How does IDXG's PE Ratio compare vs other companies in the US Healthcare Industry?

Price-To-Sales vs Industry: IDXG is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Healthcare industry average (1.5x)

Price to Sales Ratio vs Fair Ratio

What is IDXG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDXG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	1.2x

Price-To-Sales vs Fair Ratio: IDXG is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Share Price vs Fair Value

What is the Fair Price of IDXG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IDXG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IDXG's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Take a look at our analysis of IDXG's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Interpace Biosciences regulatory filings here.

Future Growth

How is Interpace Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

1/6

Future Growth Score 1/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

103.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDXG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IDXG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IDXG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IDXG's revenue (15.2% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: IDXG's revenue (15.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IDXG's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Interpace Biosciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-20.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IDXG is currently unprofitable.

Growing Profit Margin: IDXG is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IDXG is unprofitable, and losses have increased over the past 5 years at a rate of 20.5% per year.

Accelerating Growth: Unable to compare IDXG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDXG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.9%).

Return on Equity

High ROE: IDXG has a negative Return on Equity (-582.51%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Interpace Biosciences's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IDXG's short term assets ($13.1M) do not cover its short term liabilities ($16.9M).

Long Term Liabilities: IDXG's short term assets ($13.1M) do not cover its long term liabilities ($19.3M).

Debt to Equity History and Analysis

Debt Level: IDXG's net debt to equity ratio (341%) is considered high.

Reducing Debt: IDXG's debt to equity ratio has increased from 17.5% to 470.8% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IDXG has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: IDXG is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

Dividend

What is Interpace Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IDXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IDXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IDXG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDXG's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IDXG has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure

CEO

Tom Burnell (60 yo)

1.67yrs

Tenure

US$588,352

Compensation

Dr. Thomas W. Burnell, also known as Tom, Ph D., serves as the President, Chief Executive Officer and Director at Interpace Biosciences, Inc. since December 01, 2020. He serves as the President and Chief E...

CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD588.35K) is about average for companies of similar size in the US market ($USD770.24K).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: IDXG's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Experienced Board: IDXG's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/10 00:00
End of Day Share Price	2022/08/10 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31